MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into c ...

Leerink Partners maintains an "Outperform" rating for GoodRx Holdings Inc. (NASDAQ:GDRX), indicating potential for above-market performance.The stock experienced a significant drop of 18.78% today, now priced at $1.99.GoodRx's recent Q4 2025 earnings call provided crucial insights into its financial health, with a focus on earnings, revenue, and profit margins.GoodRx Holdings Inc. (NASDAQ:GDRX) is a company that provides consumers with information and tools to compare prescription drug prices and find disco ...

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the integration of Tevogen.AI [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Background - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms to develop advanced therapies across multiple areas [4]. - Tevogen Bio has completed a proof-of-concept clinical trial for its T cell therapy, with a pipeline that includes virology, oncology, and neurology [5]. - Tevogen.AI aims to transform drug development by improving target detection and clinical trial design through predictive technologies [6]. Group 3: Future Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions [3][7].

LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the TD Cowen 46th Annual Health Care Conference in Boston, MA. The Company is scheduled to present on Tuesday, March 3 at 10:30 a.m. Eastern Time. A live webcast of t ...

Back in November, I stated that Tempus AI, Inc. ( TEM ) is a good bet for the future of healthcare. In that analysis, I found good growth in their data set and their testing volumes. Furthermore, their financialsI'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma Sigma International Business Honor Society. My core values are: Excellence, Integrity, Transparency, ...

Core Insights - Tempus AI, Inc. (TEM) is identified as a promising investment opportunity in the healthcare sector due to its strong growth in data sets and testing volumes [1] Financial Performance - The financials of Tempus AI, Inc. indicate positive trends, supporting the notion of its potential for future growth [1]

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the addition of Tevogen.AI's capabilities [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Profiles - Tevogen is focused on creating a socially integrated healthcare enterprise that emphasizes affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms [4]. - Sciometrix provides enterprise care management, digital patient engagement, predictive analytics, and value-based care solutions to healthcare organizations across the nation [8]. Group 3: Strategic Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers [3][7]. - The integration of Clinicus is expected to accelerate Tevogen's commercialization readiness by aligning clinical development with real-world patient engagement and outcomes tracking [11].

Spok (NasdaqGS:SPOK) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAl Galgano - Head of Investor RelationsCalvin Rice - CFODavid Wright - President and Managing MemberMike Wallace - COOVince Kelly - CEOConference Call ParticipantsAnderson Schock - MedTech Equity Research AnalystOperatorGreetings, welcome to the Spok Holdings, Inc. Q4 2025 earnings results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal ...

Datavault AI Inc. (NASDAQ:DVLT) is one of the best penny stocks under $1 to buy right now. On February 23, Datavault AI and Wellgistics Health Inc. (NASDAQ:WGRX) announced an expansion of their partnership to develop a Healthcare-as-a-Service/HaaS model powered by blockchain-enabled smart contracts. This initiative builds on their existing PharmacyChain technology, which currently digitizes the tracking of prescription drugs from script to fulfillment. The expanded collaboration will integrate Datavault ...

Here's a look at the details from the report   TEM stock is moving. Watch the price action here.The Details: Tempus AI reported quarterly losses of four cents per share, in line with the consensus estimate, according to data from Benzinga Pro.Quarterly revenue came in at $367.21 million, which beat the Street estimate of $362.29 million and was up from $200.68 million in the year-ago period.Tempus AI reported the following fourth quarter highlights:“In 2025, Tempus continued to set the standard for what it ...